Investigational drug · Phase 3
hUC-MSCs
Also called: mesenchymal stem cells, MSC, L2-01 adipose-derived mesenchymal stem cells, Double dose
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
38
Any phase or sponsor naming "hUC-MSCs"
First trial start
2018
Oct 1, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "hUC-MSCs", any sponsor or status.
Conditions studied
As listed on its trial records.
- Knee Osteoarthritis
- Crohn&Amp;#39;s
- Crohn&Amp;#39;s Disease (CD)
- Systemic Lupus Erythematosus (SLE)
- Premature Ovarian Insufficiency
- Acute Ischemic Stroke AIS
- Osteoarthritis, Knee
- Lupus Nephritis
- Lupus Erythematosus
- Coronary Artery Bypass Grafting (CABG)
Approved drugs for the same conditions: Stroke prevention · Crohn's disease · Lupus (SLE) · Osteoarthritis · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "hUC-MSCs" as an intervention, largest first.
- Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)Pivotal-lookingStatus unknown
Chinese Academy of SciencesGovernment (non-federal)
NCT03033277 · 320 participants (planned) · Start Feb 2016 · Primary completion Apr 2017
Drug: Placebo transplantation; HUC-MSCs transplantation · For: Primary Ovarian Insufficiency
Sites: Beijing, China
- A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Min LongAcademic, hospital or other
NCT07183761 · 140 participants (planned) · Start Oct 1, 2025 · Primary completion Apr 1, 2028
Drug: Experimental Group; Conventional therapy group · For: Diabetic Peripheral Neuropathy (DPN)
Sites: Chongqing, China
Limin RongAcademic, hospital or other
NCT02481440 · 102 participants · Start Mar 30, 2018 · Primary completion Mar 31, 2020
Drug: human umbilical cord mesenchymal stem cells (hUC-MSCs) · For: Spinal Cord Injuries
Sites: Guangzhou, China
- Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic StrokeNot yet recruiting
Shanghai IxCell Biotechnology Co., LTDAcademic, hospital or other
NCT07197606 · 86 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 30, 2027
Drug: Placebo; IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells) · For: Ischemic Stroke
Sites: Beijing, China
- Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active ControlActive, not recruiting
Medipost Co Ltd.Industry
NCT06798727 · 84 participants · Start Mar 20, 2023 · Primary completion Mar 20, 2027
Drug: SMUP-IA-01(low-dose); SMUP-IA-01(mid-dose) and 1 more · For: Knee Osteoarthritis
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 5 sites in all
- Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary LesionsPivotal-lookingStatus unknown
Yang YangAcademic, hospital or other
NCT02223897 · 66 participants (planned) · Start Jul 2014 · Primary completion Jun 2017
Drug: huc-MSCs; Placebo · For: Ischemic-type Biliary Lesions
Sites: Guangzhou, China
- HUC-MSC for Treatment of High-risk HPV InfectionStatus unknown
Shanghai East HospitalAcademic, hospital or other
NCT06610773 · 60 participants (planned) · Start Mar 1, 2024 · Primary completion Sep 10, 2025
Drug: hUC-MSCs; Saline+albumin · For: Human Papillomavirus Viruses; Mesenchymal Stem Cells
Sites: Shanghai, China
- Clinical Study on the Safety and Preliminary Efficacy of hUC-MSCs Intravenous Infusion Therapy for ARDSNot yet recruiting
Southeast University, ChinaAcademic, hospital or other
NCT06505941 · 60 participants (planned) · Start Jul 20, 2024 · Primary completion Nov 20, 2025
Drug: umbilical cord mesenchymal stem cell; Placebo · For: Acute Respiratory Distress Syndrome
Shenzhen Wingor Biotechnology Co., Ltd.Industry
NCT07084012 · 60 participants (planned) · Start Aug 27, 2025 · Primary completion May 31, 2027
Drug: hUC-MSCs treatment (high dose); hUC-MSCs treatment (low dose) and 1 more · For: Acute Ischemic Stroke AIS
Sites: Beijing, China
Shenzhen Wingor Biotechnology Co., Ltd.Industry
NCT07775391 · 59 participants (planned) · Start Aug 3, 2026 · Primary completion Sep 30, 2028
Drug: hUC-MSCs Injection (Phase I); hUC-MSCs Injection (Phase IIa) and 1 more · For: Premature Ovarian Insufficiency
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- A let-7a-5p-engineered extracellular vesicle-laden bioactive scaffold promotes immunomodulation and regeneration of segmental tracheal defects.
Liu B, Wei N, Liang L, et al. · Bioact Mater 2027
- 3D culture-derived MSC EV facilitate repair by activating microglial autophagy in spinal cord injury.
Liu H, Li X, Li M, et al. · Bioact Mater 2027
- Spatial mechanopriming of multicellular interfaces drives cytoskeletal-to-nuclear remodeling to boost therapeutic efficacy of stem cells.
Bayaraa O, Lee NH, Kim SH, et al. · Bioact Mater 2027
- A topologically engineered hydrogel platform targeting IL11 promotes renal repair after partial nephrectomy.
Yu Z, Dong X, Li F, et al. · Bioact Mater 2027
- Mitochondria-rich cytochalasomes as an intravenously deliverable vesicle platform for ischemic heart disease.
Gao X, Zhang L, Xu L, et al. · Bioact Mater 2027
- Targeting the lactate/P300/H3K18la epigenetic pathway with a mechanoadaptive biomimetic hydrogel to suppress traumatic tendon heterotopic ossification.
Feng H, Ang K, Deng Z, et al. · Bioact Mater 2027
Also in development for Knee Osteoarthritis
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- JOINTSTEMPhase 32 trials
R-Bio · Knee Osteoarthritis, Osteoarthritis, Knee
- Reference DrugNSAIDsPhase 32 trials
SANGMYUNG innovation · Retinal Vein Occlusion With Macular Edema, Knee Osteoarthritis
- PTP-01MOTYS, allogeneic human placental tissue particulatePhase 31 trial
Doron Therapeutics Inc. · Knee Osteoarthritis
- Human umbilical cord blood-derived mesenchymal stem cellsSMUP-IA-01, mid-dosePhase 22 trials
Medipost Co Ltd. · Knee Osteoarthritis, Bronchopulmonary Dysplasia, BPD
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- NCR100Phase 21 trial
Nuwacell Biotechnologies Co., Ltd. · Knee Osteoarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.